WuXi Biologics: The 'Complex-Molecule Expert' Accelerating Industrialization of Innovation

WuXi Biologics published a thought-leadership piece framing itself as the full-lifecycle 'expert' for complex molecules such as bispecifics and ADCs: H1 2026 added 169 integrated projects (71% bispecific/ADC), with complex molecules over 50% of H1 revenue (up ~30% YoY); technology matrix spanning WuXiBody™, WuXiDARx™, WuXia™ TrueSite and WuXiUP™ converts complex risk into industrialization certainty.

Over the past few years, complex molecules such as bispecific/multispecific antibodies and ADCs have risen rapidly, continuously pushing global biologics innovation to a higher dimension. According to Beacon Intelligence, as of January 2026 there were over 1,700 active bispecific/multispecific drug programs and over 1,200 active ADC programs in global R&D — complex molecules have become a major driver of today's biologics innovation. Leveraging its integrated CRDMO platform and scaled experience, WuXi Biologics is becoming the partner of choice for a growing number of complex-molecule programs: in H1 2026 it added 169 integrated projects, 71% of which were bispecific/ADC, with complex molecules exceeding 50% of H1 revenue (up ~30% YoY).

▶

If the most important task for bispecifics and ADCs over the past decade was to prove scientific value, today — as blockbuster deals emerge and programs accelerate into late-stage clinical and approvals — the industry is entering a new phase of 'complex molecules accelerating toward industrialization validation'. On the regulatory side, FDA-approved bispecifics grew from one in 2014 to 15 in 2025, and 14 ADCs have been approved by the FDA; on the capital side, Pfizer's acquisition of Seagen, J&J's acquisition of Ambrx, Merck's global-rights acquisition of CN101, and Pfizer's major collaboration with 3SBio all send the same signal: complex-molecule value has been doubly validated by regulators and capital, and competition is shifting from scientific discovery to industrialization execution efficiency.

The root of this shift is that complex-molecule technical risks do not exist in isolation — they propagate continuously across molecular design, process development, analytical characterization, clinical manufacturing and commercial supply. Industrialization efficiency therefore depends not only on whether the platform is complete, but on whether expert capability runs through the full lifecycle: from molecular design to cell-line development, process scale-up to quality analysis, clinical manufacturing to commercial supply — every step shapes the downstream path and ultimate success rate. What the complex-molecule era truly needs is a technical expert who fuses industrialization thinking, platform capability and scaled experience, and distills each program's practice into the foundation for the next success.

Industrialization thinking empowers source design. WuXi Biologics moves industrialization thinking upstream, evaluating expression, stability, purification, analysis and manufacturing needs in sync at the design stage to identify and reduce downstream risk early. The WuXiBody™ bispecific platform, for example, resolves light/heavy-chain mispairing through innovative structural design while delivering high expression, high stability and easy purification; it has supported over 50 global collaborations across frontier areas such as TCE. The company has also built platforms including SDArBody™ (VHH single-domain antibody), SkyBody™ (engineered scFv) and OmniFlic (common light chain), plus ADC technology systems such as WuXiDARx™ (precise DAR control) and WuXi Payload-Linker™ (innovative linkers and payloads).

Scaled, project-validated experience empowers development. In cell-line development, the next-generation site-specific integration CHO platform WuXia™ TrueSite delivers average bispecific expression of 7.5–10 g/L and 8–12 g/L for monoclonal antibodies, cutting customer cost by 30%–50%, with DNA-to-MCB in just 9–10 weeks (1–3 months faster than industry average); since its October 2025 launch it has been applied to 70+ programs. WuXia293™ Stable (HEK293) and the EffiX™ microbial expression platform (intracellular expression up to 20+ g/L) add complementary options. On the process side, WuXiUP™ ultra-intensified perfusion lifts productivity 5–20x over conventional processes, while WuXiUI™ continuous processing delivers 3–6x productivity gains versus traditional fed-batch.

Formulation development bridges the 'last mile' from complex molecule to patient. Around the industry trend from IV to subcutaneous (SC) delivery, WuXi Biologics has built an integrated high-dose solution: the WuXiHigh™ high-concentration platform supports protein concentrations up to 240 mg/mL, a hyaluronidase co-formulation platform enables large-volume SC dosing, and autoinjectors and wearable devices continuously optimize the development-to-patient administration experience.

Systematic thinking tackles the quality-speed-cost 'impossible triangle'. WuXi Biologics combines single-use technology (SUT) with a 'scale-out' model for flexible capacity adjustment; on quality and compliance, as of June 2026 it had passed 49 global regulatory inspections (including 23 FDA and EMA inspections). On digitalization, the PatroLab™ digital-twin platform monitors 40+ critical process parameters online, while electronic batch records (EBR) and the 'Golden Batch' mechanism move production from experience-driven to data-driven.

The industry has proven that complex molecules can create enormous innovation value; the future focus is how to convert that value into patient benefit with higher efficiency and success rates. With its integrated CRDMO platform, deep understanding of complex-molecule risk and a system validated by over a thousand programs, WuXi Biologics helps customers reduce risk, shorten timelines and raise success rates — which is exactly why a growing number of global clients choose WuXi Biologics.